Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 887-888, Issue , 2012, Pages 25-34

  Dubbelman, A C ^a   Rosing, H ^a   Thijssen, B ^a   Gebretensae, A ^a   Lucas, L ^a   Chen, H ^b   Shumaker, R ^b   Schellens, J H M ^a,c   Beijnen, J H ^a,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b EISAI INC   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Biological matrices; Cross analyte interference; E7080; LC MS MS; Metabolites

Indexed keywords

ANTI-CANCER AGENTS; BIOLOGICAL MATRIXES; CALIBRATION CURVES; CHROMATOGRAPHIC SEPARATIONS; CLINICAL PHARMACOKINETICS; CORRELATION COEFFICIENT; CV VALUE; DIETHYL ETHERS; E7080; GRADIENT ELUTION; HUMAN PLASMAS; LC-MS/MS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LOWER LIMIT OF QUANTIFICATIONS; MASS BALANCE; METHOD DEVELOPMENT; PARENT COMPOUNDS; POSITIVE ION MODE; SAMPLE VOLUME; TRIPLE-QUADRUPOLE MASS SPECTROMETER; TURBO ION SPRAY; WHOLE BLOOD;

ACETONITRILE; BIOMOLECULES; BLOOD; ETHERS; FORMIC ACID; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; METABOLITES; WOOLEN AND WORSTED YARN;

EXTRACTION;

ACETONITRILE; ETHER; FORMIC ACID; LENVATINIB; WATER;

ARTICLE; BLOOD; CHROMATOGRAPHY; CONTROLLED STUDY; FECES; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; METABOLITE; PLASMA; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; URINE;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FECES; HUMANS; LINEAR MODELS; PHENYLUREA COMPOUNDS; QUINOLINES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84862800344     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2012.01.004     Document Type: Article

References (11)

1. Matsui J., Yamamoto Y., Funahashi Y., Tsuruoka A., Watanabe T., Wakabayashi T., Uenaka T., Asada M. Int. J. Cancer 2008, 122:664.
2. Ikuta K., Yano S., Trung V.T., Hanibuchi M., Goto H., Li Q., Wang W., Yamada T., Ogino H., Kakiuchi S., Uehara H., Sekido Y., Uenaka T., Nishioka Y., Sone S. Clin. Cancer Res. 2009, 15:7229.
3. Matsui J., Funahashi Y., Uenaka T., Watanabe T., Tsuruoka A., Asada M. Clin. Cancer Res. 2008, 14:5459.
4. Glen H., Boss D.R., Morrison R., Roelvink M., Wanders J., Mazur A., Gupta A., Das A., Evans T.R., Schellens J.H. A phase I study of E7080 in patients (pts) with advanced malignancies. J. Clin. Oncol. 2008, 26(Suppl. (15)):3526.
5. Sherman S., Jarzab B., Cabanillas M., Licitra L., Pacini F., Martins R., Robinson B., Ball D., McCaffrey J., Shah M., Bodenner D., Allison R., Newbold K., Elisei R., O'Brien J., Schlumberger M. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J. Clin Oncol. 2011, 29(Suppl. (15)):5503.
6. FDA. U.S. Department of Health and Human Services, Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation. 2001 (accessed 9.1.12). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
7. Rosing H., Man W.Y., Doyle E., Bult A., Beijnen J.H., Liq J. Chromatogr. Relat. Technol. 2000, 23:329.
8. Peters F.T. Application of LC-MS in Toxicology 2006, Pharmaceutical Press, London, p. 71. A. Polettini (Ed.).
9. Snyder R.L., Kirkland J.J., Dolan J.W. Introduction to Modern Liquid chromatography 2010, John Wiley & Sons, Inc., Hoboken, NJ, p. 19.
10. Viswanathan C.T., Bansal S., Booth B., DeStefano A.J., Rose M.J., Sailstad J., Shah V.P., Skelly J.P., Swann P.G., Weiner R. Pharm. Res. 2007, 24:1962.
11. Wang W., Zhou H., Lin H., Roy S., Shaler T.A., Hill L.R., Norton S., Kumar P., Anderle M., Becker C.H. Anal. Chem. 2003, 75:4818.